Oral Polypeptide Composition for Stable Gastric Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral polypeptide drugs face challenges with low bioavailability due to stability and absorption barriers in the digestive system, leading to inefficient delivery and unpredictable therapeutic effects.
Innovation Solution
An oral polypeptide composition comprising a polypeptide molecule, medium-chain fatty acids or their salts, amino acids, and N-(8-(2-hydroxybenzoyl) amino) caprylic acid or its salts, which enhances stability and absorption in the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If polypeptide drugs are administered orally, then patient convenience and compliance improve, but bioavailability decreases due to degradation by gastric acid and intestinal enzymes
Solution Approach 1:
The patent uses SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) as a carrier molecule that mediates the interaction between the polypeptide drug and the gastric mucosa. SNAC forms a complex with the polypeptide, protecting it from enzymatic degradation and facilitating its transport across the gastric barrier into the bloodstream, thereby enabling oral administration while maintaining bioavailability
Solution Approach 2:
The invention changes the chemical environment parameters in the stomach by using SNAC to create a localized microenvironment that is less hostile to polypeptides. The carrier modifies the pH and chemical conditions around the drug molecule, preventing degradation by gastric acid and enzymes while maintaining the drug's structural integrity and biological activity
2Reliability
If higher drug doses are used to compensate for low bioavailability, then therapeutic effect may be achieved, but treatment costs and side effect risks increase
Solution Approach 1:
SNAC acts as an efficient mediator that dramatically improves the delivery efficiency of the polypeptide drug. By forming a stable complex and facilitating direct transport across the gastric barrier, SNAC ensures that a much larger proportion of the administered dose reaches the bloodstream in an active form, reducing the total quantity of drug needed to achieve therapeutic effects
3Reliability
If frequent administration is required to compensate for low bioavailability, then therapeutic levels may be maintained, but patient compliance decreases
Solution Approach 1:
The SNAC-polypeptide complex provides continuous and sustained delivery of the drug into the bloodstream. The carrier ensures steady absorption over time, maintaining therapeutic levels more effectively with less frequent dosing. This continuous action pattern improves patient compliance by reducing the burden of frequent administration while reliably maintaining therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition promotes stable absorption of polypeptide drug molecules, improving bioavailability and reducing the need for higher drug doses, thereby enhancing treatment efficacy and compliance.
Implementation Method 1
Rybelsus® uses sodium N-(8-(2-hydroxybenzoyl)amino) caprylate (SNAC) in the Eligen carriers. It increases the stability and absorption rate of semaglutide in the stomach by adjusting the pH value in the stomach and affecting the permeability of the gastric mucosa.
Data Source
AI summary
An oral polypeptide composition for improving the gastrointestinal absorption of polypeptide drugs is provided. The oral polypeptide composition includes polypeptide molecules, medium-chain fatty acids (MCFA) and their salts, amino acids and N-(8-(2-hydroxybenzoyl) amino) caprylic acid (NAC) and its salts. The oral polypeptide composition can effectively increase the plasma drug concentration of the polypeptide and improve the oral bioavailability of the polypeptide.